Aaron Cowen’s Kezar Life Sciences KZR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-716,759
Closed -$5.32M 101
2026
Q1
$5.32M Hold
716,759
0.14% 59
2025
Q4
$4.51M Hold
716,759
0.09% 69
2025
Q3
$2.8M Hold
716,759
0.07% 72
2025
Q2
$3.28M Hold
716,759
0.1% 68
2025
Q1
$3.5M Hold
716,759
0.13% 68
2024
Q4
$4.82M Hold
716,759
0.16% 65
2024
Q3
$5.54M Hold
716,759
0.18% 62
2024
Q2
$4.3M Hold
716,759
0.16% 56
2024
Q1
$6.46M Hold
716,759
0.24% 60
2023
Q4
$6.79M Hold
716,759
0.31% 50
2023
Q3
$8.53M Hold
716,759
0.46% 47
2023
Q2
$17.6M Buy
716,759
+28,000
+4% +$729K 0.94% 40
2023
Q1
$21.6M Buy
688,759
+338,333
+97% +$19.6M 0.91% 37
2022
Q4
$24.7M Buy
350,426
+22,874
+7% +$1.7M 1.04% 35
2022
Q3
$28.2M Sell
327,552
-113,678
-26% -$11M 1.17% 33
2022
Q2
$36.5M Buy
441,230
+300,234
+213% +$26.5M 1.39% 30
2022
Q1
$23.4M Hold
140,996
0.72% 45
2021
Q4
$23.6M Hold
140,996
0.46% 46
2021
Q3
$12.2M Hold
140,996
0.21% 58
2021
Q2
$7.66M Hold
140,996
0.11% 84
2021
Q1
$8.4M Hold
140,996
0.12% 78
2020
Q4
$7.36M Buy
140,996
+85,406
+154% +$4.75M 0.11% 69
2020
Q3
$2.69M Hold
55,590
0.05% 76
2020
Q2
$2.88M Buy
55,590
+46,600
+518% +$2.35M 0.06% 64
2020
Q1
$392K Buy
+8,990
New +$366K 0.01% 64

Aaron Cowen's KZR Position: Q2 2026 in Review

Aaron Cowen sold out of Kezar Life Sciences (KZR) in Q2 2026, closing a stake of 716,759 shares — an estimated $5.32M sold.

Aaron Cowen first reported a position in KZR in Q1 2020 and held it in 25 quarters. The position peaked at $36.5M in Q2 2022. 0 funds tracked by Wall St. Rank hold KZR as of Q2 2026.

  • Aaron Cowen reported no remaining Kezar Life Sciences position as of Q2 2026 after selling out during the quarter.
  • Aaron Cowen sold 716,759 Kezar Life Sciences shares in Q2 2026, an estimated $5.32M.
  • Aaron Cowen first reported a position in Kezar Life Sciences in Q1 2020 and held it in 25 quarters.
  • Aaron Cowen's Kezar Life Sciences position peaked at $36.5M in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2026.

Based on Suvretta Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.